BioInvent Appoints Head of Preclinical Research
Lund, Sweden - 20 May 2009 - BioInvent International AB (OMXS:BINV) today announces that it has appointed Björn Frendeus to Vice President Preclinical Research.
Björn Frendeus, 36 years, will head BioInvent's research projects up to identification of potential product candidates for further preclinical safety evaluation. He becomes a member of the Management group and reports to the CEO.
Björn Frendeus started his career in BioInvent in 2000 and has until today had leading roles in the development of several of current product candidates. Björn has a PhD from Lund University in Immunology.
Svein Mathisen, CEO of BioInvent, commented, "Björn has in several years contributed strongly to the development of our portfolio. These contributions have been crucial in our commercial achievements the last two years. Developing the talents Björn represents are a strength and we are very pleased to extend his area of responsibility through this appointment."
- END -
For further information, please contact:
BioInvent International AB
Svein Mathisen
President & CEO
Tel: +46 (0)46-286 85 67
Mobile: +46 (0)708-97 82 13
E-mail: [email protected]
Cristina Glad
Executive Vice President
Tel: +46 (0)46-286 85 51
Mobile: +46 (0)708-16 85 70
E-mail: [email protected]
College Hill (media enquiries)
Holly Griffiths, Sue Charles and John McIntyre
Tel: +44 (0)20 7457 2020
E-mail: [email protected]
Notes to Editors:
About BioInvent
BioInvent International AB, listed on the NASDAQ OMX Stockholm (BINV), is a research-based pharmaceutical company that focuses on developing antibody drugs. The Company is currently running innovative drug projects within the areas of thrombosis, cancer and atherosclerosis. The Company has signed various strategic alliances around these product candidates and is developing them in collaboration with partners including Genentech, Roche and ThromboGenics.
These projects are based around a competitive and in substance patented antibody development platform. The scope and strength of this platform is also utilised by partners, such as ALK-Abelló, Bayer HealthCare, ImmunoGen, OrbusNeich, Sanofi-Aventis, UCB and XOMA. More information is available at www.bioinvent.com.
BioInvent International AB (publ) Co. reg. No. 556537-7263, Address: Sölvegatan 41 Mailing address: SE-223 70 LUND Tel: +46 (0)46 286 85 50 [email protected] www.bioinvent.com
Information disclosed in this press release is provided herein pursuant to the Swedish Securities Markets Act and/or the Swedish Financial Instruments Trading Act. The information was submitted for publication at 11.15 a.m. CET, on 20 May, 2009.